A 38-year-old man with generalized anxiety disorder and depression has been on venlafaxine (SNRI) 150 mg daily for 8 weeks with partial response. He now reports new-onset tremor, increased heart rate (92 bpm), and mild hypertension (148/92 mmHg). He is otherwise tolerating the medication. What is the most appropriate next step?

Explanation

## Management of SNRI-Related Adverse Effects with Partial Response ### Clinical Context This patient is experiencing dose-related adverse effects (tremor, tachycardia, hypertension) from venlafaxine, a norepinephrine-serotonin reuptake inhibitor (SNRI). However, he has shown partial therapeutic response, suggesting the current dose is having some benefit. The challenge is balancing efficacy with tolerability. ### SNRI Adverse Effect Profile **Key Point:** SNRIs, particularly at higher doses, cause noradrenergic adverse effects: tremor, tachycardia, hypertension, and insomnia. These effects are dose-dependent and more pronounced than with SSRIs. | Adverse Effect | Mechanism | Onset | Management | |---|---|---|---| | Tremor, tachycardia | Noradrenergic activation | Days to weeks | Dose reduction or beta-blocker | | Hypertension | ↑ Norepinephrine reuptake inhibition | Weeks | Dose adjustment or antihypertensive | | Insomnia | Noradrenergic stimulation | Early | Timing adjustment or sedating co-medication | ### Optimal Management Strategy **High-Yield:** When an SNRI causes dose-related adverse effects but shows partial efficacy: 1. **Reduce the dose** to a lower therapeutic level (e.g., 150 → 75 mg) 2. **Add a beta-blocker** (e.g., propranolol 20–40 mg BID) to manage noradrenergic symptoms (tremor, tachycardia) 3. **Monitor BP and reassess** in 2–4 weeks 4. If response remains inadequate, consider re-escalation or augmentation **Clinical Pearl:** Beta-blockers are particularly useful in SNRI-induced tremor and tachycardia because they directly counteract noradrenergic overstimulation without interfering with the antidepressant mechanism. ### Why Not Discontinue? - The patient has shown partial response; abrupt discontinuation risks relapse and withdrawal symptoms - SNRI withdrawal can cause dizziness, paresthesias, and mood destabilization - Dose reduction with symptomatic management preserves the therapeutic benefit ### Why Not Increase Dose? - Increasing venlafaxine to 225 mg would worsen noradrenergic adverse effects (tremor, hypertension, tachycardia) - The patient is already experiencing dose-limiting toxicity [cite:KD Tripathi 8e Ch 19; Harrison 21e Ch 470] ```mermaid flowchart TD A[SNRI at therapeutic dose<br/>Partial response +<br/>Noradrenergic AEs]:::outcome --> B{Adverse effects<br/>intolerable?}:::decision B -->|Yes, severe| C[Discontinue,<br/>switch class]:::action B -->|Yes, moderate| D[Reduce SNRI dose<br/>Add beta-blocker]:::action D --> E[Reassess in 2-4 weeks]:::action E --> F{Response adequate<br/>AEs controlled?}:::decision F -->|Yes| G[Continue maintenance]:::action F -->|No - still inadequate| H[Consider re-escalation<br/>or augmentation]:::action F -->|No - persistent AEs| I[Switch to SSRI]:::action ```